“Triple Threat-Triple Benefit: The Rise of GLP1-GCG-FGF21 Tritagonists in Tomorrow’s Metabolic Medicine ”. 2025. Diabzen 3 (3): 43-48. https://www.thediabzen.com/index.php/d/article/view/19.